The firm said that it has begun developing its own products using synthetic affinity reagent technology acquired five years ago from the University of Leicester.
Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.
The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.
Ortho's assay, which aids in quickly and accurately diagnosing heart attacks, runs on its new Vitros XT 7600 Integrated System, among other Ortho systems.
